Last reviewed · How we verify
Hydroxycamptothecin for Injection
Hydroxycamptothecin inhibits topoisomerase I, preventing DNA relaxation and causing DNA damage in rapidly dividing cancer cells.
Hydroxycamptothecin inhibits topoisomerase I, preventing DNA relaxation and causing DNA damage in rapidly dividing cancer cells. Used for Colorectal cancer, Gastric cancer, Lung cancer.
At a glance
| Generic name | Hydroxycamptothecin for Injection |
|---|---|
| Sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Drug class | Topoisomerase I inhibitor |
| Target | Topoisomerase I |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Hydroxycamptothecin is a camptothecin derivative that binds to and stabilizes the topoisomerase I-DNA complex, preventing the enzyme from completing its catalytic cycle. This leads to accumulation of DNA single-strand breaks and cell death, particularly in rapidly proliferating cancer cells. It is a semi-synthetic analog of camptothecin with improved stability and bioavailability compared to the parent compound.
Approved indications
- Colorectal cancer
- Gastric cancer
- Lung cancer
- Ovarian cancer
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Gastrointestinal toxicity (diarrhea, nausea, vomiting)
- Alopecia
- Fatigue
- Elevated liver enzymes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |